首頁 > 市場調查報告書 > 醫療設備

感測器生技設備

市場調查報告書

商品編碼

1733220

2026 年至 2032 年生物感測器市場類型、應用、技術、最終用戶和地區分析

Biosensors Market By Type (Wearable, Implantable), Application (Medical Diagnostics, Food Analysis), Technology (Electrochemical, Optical), End-Users (Hospitals & Clinics, Diagnostic Laboratories), & Region for 2026-2032

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年生物感測器市場評估

奈米技術和微電子技術的創新正在提高靈敏度和特異性，促進生物感測器的採用。慢性病的增加將推動對生物感測器提供的持續監測解決方案的需求，使市場規模在 2024 年超過 333 億美元，並在 2032 年達到約 605 億美元的估值。

此外，醫療保健基礎設施和研發方面的投資不斷增加，推動了先進生物感測技術的發展，刺激了生物感測器的普及。對照護現場診斷的需求不斷成長，推動了可攜式和易於使用的生物感測器的採用，2026 年至 2032 年的複合年成長率為 8.55%。

生物感測器市場定義/概述

生物感測器是一種將生物反應轉換為電訊號的分析裝置，可以檢測和量化各種物質。生物感測器通常由生物檢驗元件（例如酶、抗體或微生物）和將生化相互作用轉換為可測量訊號的換能器組成。該技術可提供快速、靈敏和特異性的分析，使其在各個領域都具有價值。

生物感測器的應用範圍廣泛且多樣。在醫療保健領域，它們用於監測糖尿病患者的血糖濃度、檢測病原體以及進行照護現場診斷。環境監測也是一個重要領域，生物感測器可以檢測水和土壤中的污染物和病原體，有助於確保公共和環境保護。此外，生物感測器還用於食品安全，可以快速檢測污染物並確保食品品質。

勞動力管理如何提高生物感測器的採用率？

慢性病盛行率的上升以及對快速且準確診斷解決方案的需求不斷成長，推動著生物感測器市場的發展。根據世界衛生組織 (WHO) 的《2023 年全球健康報告》，糖尿病影響全球約 5.37 億成年人，推動了對用於持續血糖監測的生物感測器的需求。人工智慧和物聯網功能的整合透過即時數據分析和遠端患者監護徹底改變了疾病監控和管理。隨著雅培實驗室於 2024 年 3 月推出新款 FreeStyle Libre 4 系統，這一趨勢進一步增強，該系統具有更高的準確性和智慧型手機連接性，可用於糖尿病管理。

COVID-19 疫情加速了醫療保健領域對就地檢驗和生物感測器技術的採用。美國疾病管制與預防中心報告稱，到2023年，利用生物感測器技術的快速診斷測試與傳統實驗室檢測方法相比，平均診斷時間縮短了65%。對早期疾病檢測和預防性醫療保健的重視正在推動對生物感測器研究和開發的大量投資。 2024年2月，羅氏診斷推出了其最新的用於心臟生物標記檢測的生物感測器平台。

環境監測和食品安全問題已成為採用生物感測器技術的主要驅動力。歐洲食品安全局 2023 年的報告顯示，基於生物感測器的食品檢測方法檢測污染物的速度比傳統檢測方法快 40%。微型和攜帶式生物感測器的發展正在擴大其在從農業到環境保護等各個行業的應用。賽默飛世爾科技於 2024 年 1 月收購了主要企業，並推出了用於環境污染物檢測的新型連接複用生物感測器平台，突顯了這一市場變革。

缺乏標準化測試和品管措施是否會抑制生物感測器市場的成長？

資料管理和互通性問題也帶來了挑戰。隨著生物感測器產生的數據量越來越大，確保有效的數據整合和分析將變得至關重要。許多醫療保健提供者和實驗室難以管理這些數據，尤其是在將生物感測器整合到現有系統時，這可能會阻礙臨床應用。

另一個主要限制因素是監管核准流程的複雜性。生物感測器，尤其是用於醫療應用的生物感測器，必須經過嚴格的測試和檢驗，以滿足安全性和有效性的標準。這個漫長而昂貴的核准過程減緩了新生物感測器產品的市場推廣，並抑制了投資和創新。

此外，整個生物感測器產業缺乏標準化測試和品管措施。如果沒有標準化的協議，製造商就很難確保產品的可靠性和可重複性。這種不一致性可能會導致使用者和醫療保健專業人員對生物感測器的性能產生懷疑，從而減緩市場接受度。

Innovations in nanotechnology and microelectronics enhance the sensitivity and specificity is propelling the adoption of biosensors. Increasing prevalence of chronic diseases drives demand for continuous monitoring solutions provided by biosensors is driving the market size surpass USD 33.3 Billion valued in 2024 to reach a valuation of around USD 60.5 Billion by 2032.

In addition to this, increased investment in healthcare infrastructure and research fuels the development of advanced biosensing technologies is spurring up the adoption of biosensors. Rising demand for point-of-care diagnostics drives the adoption of portable and user-friendly biosensors is enabling the market to grow at a CAGR of 8.55% from 2026 to 2032.

Biosensors Market: Definition/Overview

Biosensors are analytical devices that convert a biological response into an electrical signal, allowing for the detection and quantification of various substances. They typically consist of a biological sensing element, such as enzymes, antibodies, or microorganisms, integrated with a transducer that converts the biochemical interaction into a measurable signal. This technology offers rapid, sensitive, and specific analysis, making it invaluable in various fields.

The applications of biosensors are vast and diverse. In healthcare, they are used for monitoring glucose levels in diabetic patients, detecting pathogens, and conducting point-of-care diagnostics. Environmental monitoring is another critical area, where biosensors can detect pollutants and pathogens in water and soil, helping to ensure public safety and environmental protection. Additionally, biosensors find uses in food safety, allowing for the rapid testing of contaminants and ensuring the quality of food products.

How will Workforce Management Increase Adoption of Biosensors?

The rising prevalence of chronic diseases and the growing demand for rapid, accurate diagnostic solutions have significantly propelled the biosensors market forward. According to the World Health Organization's 2023 Global Health Report, diabetes affects approximately 537 million adults worldwide, driving the need for continuous glucose monitoring biosensors. The integration of artificial intelligence and IoT capabilities has revolutionized disease monitoring and management through real-time data analysis and remote patient monitoring. This trend gained momentum when Abbott Laboratories launched their new FreeStyle Libre 4 system in March 2024, featuring enhanced accuracy and smartphone connectivity for diabetes management.

The COVID-19 pandemic has accelerated the adoption of point-of-care testing and biosensor technology across healthcare settings. The U.S. Centers for Disease Control and Prevention reported that rapid diagnostic tests utilizing biosensor technology reduced average diagnosis time by 65% in 2023 compared to traditional laboratory testing methods. The emphasis on early disease detection and preventive healthcare has driven substantial investments in biosensor research and development. In February 2024, Roche Diagnostics introduced their latest biosensor platform for cardiac biomarker detection, offering results in under 8 minutes with improved sensitivity.

Environmental monitoring and food safety concerns have emerged as crucial drivers for biosensor technology adoption. The European Food Safety Authority's 2023 report indicated that biosensor-based food testing methods detected contaminants 40% faster than conventional testing approaches. The development of miniaturized, portable biosensors has expanded their applications across various industries, from agriculture to environmental protection. This market evolution was highlighted when Thermo Fisher Scientific announced in January 2024 its acquisition of a leading biosensor technology company and the launch of their new multiplex biosensor platform for environmental pollutant detection.

Will Lack of Standardized Testing and Quality Control Measures Restraining Biosensors Market Growth?

Data management and interoperability issues also present challenges. As biosensors increasingly generate large volumes of data, ensuring effective data integration and analysis becomes crucial. Many healthcare providers and laboratories struggle with managing this data, particularly when integrating biosensors with existing systems, which can hinder their adoption in clinical settings.

Another significant restraint is the complexity of regulatory approval processes. Biosensors, especially those used in medical applications, must undergo rigorous testing and validation to meet safety and efficacy standards. This lengthy and often costly approval process can slow down the introduction of new biosensor products into the market, deterring investment and innovation.

Additionally, there is a lack of standardized testing and quality control measures across the biosensor industry. Without standardized protocols, it can be difficult for manufacturers to ensure the reliability and reproducibility of their products. This inconsistency can lead to skepticism among users and healthcare professionals regarding the performance of biosensors, slowing market acceptance.

Category-Wise Acumens

Will Rise in Adoption of Non-Wearable Biosensor Drive Biosensors Market Growth?

The non-wearable biosensor segment dominates the market, primarily driven by its widespread application in clinical diagnostics and laboratory settings. According to the National Institutes of Health's 2023 Medical Device Report, non-wearable biosensors accounted for 65% of all biosensor implementations in healthcare facilities, demonstrating their crucial role in diagnostic procedures. These devices offer superior sensitivity and specificity compared to their wearable counterparts, making them indispensable for accurate disease detection and monitoring. The segment's growth was further emphasized when Siemens Healthineers launched their advanced non-wearable biosensor platform in March 2024, featuring multiplexed detection capabilities for various biomarkers.

Point-of-care testing applications have significantly boosted the adoption of non-wearable biosensors in emergency departments and primary care settings. The U.S. Food and Drug Administration reported that non-wearable biosensor-based diagnostic tests reduced patient waiting times by 75% in 2023 compared to traditional laboratory methods. These devices enable rapid decision-making and immediate treatment initiation, particularly crucial in critical care scenarios. This trend was highlighted when Medtronic introduced its new non-wearable biosensor system in February 2024, designed for rapid cardiac biomarker detection with enhanced accuracy and reduced analysis time.

Will Rise in Adoption of Electrochemical Biosensors fuel Growth of Biosensors Market?

Electrochemical biosensors have established dominance in the market due to their exceptional sensitivity, cost-effectiveness, and rapid response capabilities in detecting biological analytes. The National Institute of Standards and Technology reported in 2023 that electrochemical biosensors demonstrated a 95% accuracy rate in glucose monitoring applications, significantly higher than other biosensor technologies. Their ability to provide quantitative results with minimal sample preparation has made them indispensable in clinical diagnostics and point-of-care testing. This technological advancement was highlighted when Dexcom introduced its next-generation electrochemical continuous glucose monitoring system in March 2024, featuring enhanced accuracy and extended sensor life.

The versatility of electrochemical biosensors in detecting various biomarkers has driven their widespread adoption in medical diagnostics and disease monitoring. According to the U.S. Food and Drug Administration's 2023 Medical Device Report, electrochemical biosensors accounted for 70% of all approved biosensor-based diagnostic devices. These sensors excel in providing real-time, label-free detection of biomolecules with high specificity. In February 2024, Roche Diagnostics launched their innovative electrochemical biosensor platform for cardiac biomarker detection, incorporating advanced electrode materials and improved signal processing capabilities.

Country/Region Wise Acumens

Will Advanced Healthcare Infrastructure in North America Bolster Expansion of Biosensors Market?

North America maintains its leadership position in the biosensors market, driven by advanced healthcare infrastructure and substantial investments in medical technology research and development. The U.S. Centers for Disease Control and Prevention reported in 2023 that biosensor adoption in American healthcare facilities increased by 45% compared to the previous year, highlighting the region's rapid technological integration. The presence of major market players and favorable regulatory frameworks has accelerated innovation in biosensor technology. This dominance was further solidified when Dexcom announced in March 2024 a USD 500 Million investment in expanding its biosensor manufacturing facilities across the United States, focusing on next-generation continuous glucose monitoring systems.

The region's robust pharmaceutical and biotechnology sectors have significantly contributed to biosensor market growth. According to the National Institutes of Health's 2023 Biomedical Research Report, North American institutions accounted for 55% of global biosensor-related patents and research publications. The increasing prevalence of chronic diseases and the growing demand for point-of-care diagnostics continue to drive market expansion. In February 2024, Abbott Laboratories secured FDA approval for their latest biosensor platform, featuring enhanced sensitivity for multiple biomarker detection and improved connectivity options for remote patient monitoring.

Will Rising Technological Advancements and Research Collaborations Enhance Adoption of Biosensors in Asia Pacific?

The Asia Pacific biosensors market is experiencing rapid growth, driven by increasing healthcare expenditure, rising chronic disease prevalence, and growing awareness of point-of-care diagnostics. Countries like China, Japan, and India are at the forefront of this expansion, with their large populations and improving healthcare infrastructure. According to a report by the World Health Organization, the Asia Pacific region accounted for 37% of the global medical devices market in 2020, indicating a strong foundation for biosensor adoption.

Technological advancements and research collaborations are further propelling the market forward. Universities and research institutions across the region are partnering with industry leaders to develop innovative biosensor technologies. For instance, in March 2024, the National University of Singapore announced a breakthrough in developing a highly sensitive graphene-based biosensor for rapid detection of infectious diseases. This innovation has the potential to revolutionize disease diagnosis and management in the region.

Competitive Landscape

The biosensors market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the biosensors market include:

Abbott Laboratories
Siemens Healthineers
Roche Diagnostics
Medtronic
Honeywell International, Inc.
Danaher Corporation
Johnson & Johnson
Thermo Fisher Scientific, Inc.
GlaxoSmithKline plc
Bayer AG
GE Healthcare
Sensirion AG
Molecular Devices (A part of Danaher)
Bio-Rad Laboratories, Inc.
Schott AG
Analytik Jena AG
Eppendorf AG
Novartis AG
Acon Laboratories, Inc.
Zymergen, Inc.
Biosensors Market Latest Developments
In October 2023, BioTech Innovations announced a partnership with HealthSense Technologies to develop advanced biosensors for real-time health monitoring, focusing on chronic disease management.
In September 2023, researchers at Stanford University unveiled a groundbreaking biosensor capable of detecting multiple biomarkers from a single drop of blood, aiming for faster diagnostic capabilities in clinical settings.

1 INTRODUCTION OF GLOBAL BIOSENSORS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BIOSENSORS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BIOSENSORS MARKET, BY TYPE

5.1 Overview
5.2 Wearable
5.3 Implantable
5.4 Non-Wearable

6 GLOBAL BIOSENSORS MARKET, BY END-USERS

6.1 Overview
6.2 Hospitals & Clinics
6.3 Diagnostic Laboratories
6.4 Food & Beverage
6.5 Environmental Monitoring Agencies
6.6 Pharmaceutical & Biotechnology Companies
6.7 Research Institutes & Academia

7 GLOBAL BIOSENSORS MARKET, BY TECHNOLOGY

7.1 Overview
7.2 Electrochemical
7.3 Optical
7.4 Piezoelectric
7.4 Thermal
7.5 Nanomechanical

8 GLOBAL BIOSENSORS MARKET, BY APPLICATION

8.1 Overview
8.2 Medical Diagnostics
8.3 Food Analysis
8.4 Environmental Monitoring
8.5 Industrial Process Control
8.6 Agricultural Testing, Biodefense

9 GLOBAL BIOSENSORS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL BIOSENSORS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Siemens Healthineers
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Roche Diagnostics
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Medtronic
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Honeywell International, Inc.
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Danaher Corporation
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 LifeSensors Inc.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Johnson & Johnson
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Thermo Fisher Scientific, Inc.
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments